Skip to main content
OpenTrials

Clinical trial condition

Neuroendocrine Tumors

Explore clinical trials studying Neuroendocrine Tumors. Study availability and eligibility vary by location and protocol.

2,795 public trials 505 recruiting studies
Refine in advanced search Browse all conditions

Neuroendocrine Tumors trial results

Completed

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

NCT00055562

Conditions
Melanoma, Neoplasm Metastasis, Neoplasms, +13 more
Locations
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • University of Southern California Norris Cancer Center Los Angeles, California, United States
  • UCLA Los Angeles, California, United States
  • St. Francis Memorial Hospital San Francisco, California, United States
View all 31 locations
View Trial Details
Terminated

A Study of ASP1012 in Adults With Solid Tumors

NCT06171178

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • The Angeles Clinic and Research Institute Los Angeles, California, United States
  • Hoag Memorial Hospital Presbyterian Newport Beach, California, United States
  • Emory Winship Cancer Institute Atlanta, Georgia, United States
  • University of Iowa Hospitals Iowa City, Iowa, United States
View Trial Details
Terminated

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • Moores Cancer Center ( Site 0116) La Jolla, California, United States
  • The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131) Los Angeles, California, United States
  • California Pacific Medical Center - Pacific Campus ( Site 0111) San Francisco, California, United States
View all 205 locations
View Trial Details
Terminated

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

NCT05130866

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cranial Nerve Diseases, Cranial Nerve Neoplasms, +25 more
Locations
  • House Institute Los Angeles, California, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Children's National Hospital Washington D.C., District of Columbia, United States
  • University of Florida Gainesville, Florida, United States
View all 15 locations
View Trial Details

Related conditions